Harvard Bioscience Inc (HBIO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$8.02+0.25%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · HBIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -86.3% |
| Our one-year growth estimate | diamond | 5.8% |
Growth built into the price is above our model estimate.
The price assumes 92.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 25 industry peers · Company calendar date is not available
HBIO — earnings miss
Dated 2026-08-11
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: This would indicate that the company is struggling to maintain growth momentum. It would also raise concerns about the effectiveness of their product strategies.
Worry ifQ3 revenue growth reported below 3% year over year.
Less concerning ifQ3 revenue growth reported at 3% or higher year over year.
Why it matters: If the health care sector's revenue growth speeds up, it could help Harvard Bioscience. This would signal a better environment for the company.
Supportive ifHealth care sector revenue growth returns to near 10 percent or higher.
Worry ifThe health care sector's revenue growth is slowing down. It is below current levels.
Why it matters: This range indicates if the company maintains its growth momentum. Consistent growth is key for investor confidence.
Supportive ifQ3 revenue reported within the range of $21.0 million to $22.6 million.
Worry ifQ3 revenue falls below $21.0 million.
Why it matters: Meeting this target would show Harvard Bioscience is on track for growth. It is key for investor confidence.
Supportive ifQ2 revenue growth of 2% to 4% year over year.
Worry ifQ2 revenue growth below 2% year over year.
Why it matters: This growth is key. It shows the company's financial health and how well it runs.
Supportive ifAdjusted EBITDA was between $1.0 million and $2.0 million for Q2. This shows growth.
Worry ifAdjusted EBITDA is below $1.0 million. This shows there are problems with operations.
Why it matters: This project is important. It helps make things run better and costs less.
Supportive ifManagement gives a clear update on Project Viking. It shows that progress is being made.
Worry ifNo updates or negative news on Project Viking's status.
Why it matters: Hitting this target would prove good cost control and smooth operations.
Supportive ifAdjusted EBITDA for Q3 meets or exceeds $2.5 million.
Worry ifAdjusted EBITDA for Q3 falls below $1.5 million.
Why it matters: If it falls below this level, it shows problems with costs or products. This can hurt profits.
Worry ifAdjusted gross margin is below 57%.
Less concerning ifAdjusted gross margin reported at 57% or higher.
Why it matters: If the company meets or beats this guidance, it shows strong demand and sales.
Supportive ifQ3 revenue growth guidance meets or exceeds 5% year-over-year.
Worry ifQ3 revenue growth guidance falls below 3% year-over-year.
Why it matters: This means the company is not managing costs well or growing profits as planned.
Worry ifAdjusted EBITDA growth is below 6%.
Less concerning ifAdjusted EBITDA growth is 6% or higher.
Why it matters: This margin range shows if the company can make money while growing. It reflects cost control.
Supportive ifAdjusted gross margin is between 56% and 58%.
Worry ifAdjusted gross margin falls below 56%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$160 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $638 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,524 loss on $10,000 · 45.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.